CAR-T cells have shown promise for treating lymphoma, leukemia, and myeloma. Clinical trials currently in progress are using a new kind of CAR-T cells, which are grown in a unique way that doctors hope will be better at attacking cancer cells, according to Dr. Nina Shah of the University of California, San Francisco.
Dr. Shah points out that there are some exclusions when it comes to patients who can participate in these trials. Patients must be healthy enough to undergo therapy that can be intensive, but also sick enough to need this kind of experimental treatment. The ideal patient for this type of trial is someone who has not responded to any other treatments.
CAR-T therapy is showing really promising results in current clinical trials. It involves genetically modifying your own cells so they can attack cancer.
For patients diagnosed with CLL, the go-to treatment option is usually some form of chemo-immunotherapy. But this is not an option for all patients.
Oral Medicine for Relapsed CLL: Venetoclax
Oral Medicine for CLL: Ibrutinib
Oral Medicine for Relapsed CLL